Monitors should watch for Nasdaq's formal determination on continued listing and the outcome of the strategic alternative process. The side letter's cash lockbox and potential repayment obligation constrain management's use of the proceeds, making a near-term liquidity crisis or forced strategic transaction likely. The warrants' 200% coverage and $6.57 exercise price create a massive overhang that will pressure the stock toward that level. Any decision not to proceed with the strategic alternative triggers a cash repayment that could wipe out the entire net cash raise, making this less of a growth capital infusion and more of a bridge-to-sale structure.
Price Chart
Executive Summary
ENDRA Life Sciences announced a ~$3.8 million private placement on May 27, 2026, issuing 578,387 shares/pre-funded warrants and 1,156,774 common warrants (exercise price $6.57) to one accredited investor, with expected closing on May 28, 2026. The capital raise is structured to address a Nasdaq stockholders' equity deficiency (as of April 2026, equity was $2.26M vs. $2.5M minimum) and includes a side letter requiring the company to maintain the $3.8M proceeds in a segregated account, tied to a potential strategic alternative process. The highly dilutive structure — pre-funded warrants exercisable at $0.0001 and common warrants at $6.57 covering 200% of shares sold — coupled with Nasdaq listing uncertainty and a lockbox cash restriction, signals acute financial distress and heavily dilutes existing holders.
Key Financial Metrics
Key Facts
- ~$3.8 million gross proceeds from private placement of 578,387 shares/pre-funded warrants and 1,156,774 common warrants at $6.57 per combined unit
- Common warrants are exercisable for 200% of the shares sold, at $6.57 per share, with cashless exercise available after six months
- Pre-funded warrants have a nominal exercise price of $0.0001 per share; a portion (324,372 shares) and all common warrants require stockholder approval before exercisability
- The sole purchaser is LHE LNG Holdings LLC; the placement agent receives an additional 100,000 pre-funded warrants as compensation
- Nasdaq staff notified ENDRA on April 20, 2026 that stockholders' equity of $2.26M (as of Dec. 31, 2025) was below the $2.5M minimum; the company requested a hearing and believes the offering restores compliance
- A side letter agreement requires ENDRA to maintain the $3.8M proceeds in a segregated bank account with a deposit control agreement until a strategic alternative closes or a repayment obligation is triggered
- The company must pay the purchaser $3.8M less the fair market value of shares if it decides not to pursue a specified strategic alternative
Financial Impact
Offering size of ~$3.8 million; 578,387 shares issued and up to 1,156,774 additional shares from warrant exercise (at $6.57), plus 100,000 placement agent warrants. Against a ~$7M market cap, potential dilution from full warrant exercise is extreme - well over 100% of current shares outstanding.
Risk Factors
- Nasdaq delisting risk remains pending formal determination; if denied, stock moves to OTC and loses institutional eligibility
- Extreme dilution: full exercise of all warrants (1,156,774 shares + 100,000 placement agent warrants) would nearly double shares outstanding from a ~$7M base
- Side letter lockbox restricts the company from freely deploying the ~$3.8M; failure to close a strategic alternative within an undefined timeline triggers a repayment that returns most of the cash to the investor
- Business is pre-commercial/revenue-stage with high cash burn; this offering may only extend runway by a few quarters at best
- The purchaser's beneficial ownership limitation of 4.99% limits near-term warrant exercise but does not eliminate the overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-061701 |
| Document: ea029221601ex4-2.htm | 0001213900-26-061701 |
| Document: ea029221601ex4-1.htm | 0001213900-26-061701 |
| Document: ea0292216-8k_endra.htm | 0001213900-26-061701 |
| Document: 0001213900-26-061701-index-headers.html | 0001213900-26-061701 |
| Document: 0001213900-26-061701-index.html | 0001213900-26-061701 |
| Document: 0001213900-26-061701.txt | 0001213900-26-061701 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 425 | $4.82 | awaiting T+5 | — | $4.96 (+2.93%) |
Oct 8, 2026 19d ago | 3 | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 8, 2026 19d ago | SC 13D | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 1, 2026 26d ago | 425 | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Oct 1, 2026 26d ago | 8-K | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Sep 25, 2026 4w ago | 425 | $5.80 $6.31 | ▲ +8.79% | ▲ +7.59% | $4.96 (−14.47%) |
Sep 9, 2026 6w ago | 425 | $5.83 $5.13 | ▼ −12.01% | ▼ −11.67% | $4.96 (−14.91%) |
Aug 17, 2026 10w ago | 8-K | $4.51 $4.75 | ▲ +5.32% | ▲ +5.52% | $4.96 (+10.00%) |
Jul 17, 2026 14w ago | 425 | $4.99 $5.23 | ▲ +4.81% | ▲ +5.50% | $4.96 (−0.58%) |
Jul 9, 2026 15w ago | 8-K | $5.49 $5.27 | ▼ −4.01% | ▼ −3.88% | $4.96 (−9.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers